全膝关节置换术中术前单独骨内注射头孢呋辛:一项证明组织浓度更优且效率提升的随机试验
骨内给药组组织药物浓度高于静脉组,且骨内750 mg组在维持有效组织浓度的同时全身暴露更低,术后3个月内无感染或药物不良事件。
要点
- 骨内头孢呋辛750 mg和1,500 mg组组织浓度均高于静脉1,500 mg组(P < 0.05)。
- 除近端胫骨骨样本外,骨内750 mg与1,500 mg组组织浓度无显著差异(P > 0.05)。
- 术后3个月内无感染或药物不良事件发生。
核心结论
- 骨内头孢呋辛750 mg或1,500 mg在全膝关节置换中达到的组织浓度高于静脉1,500 mg。
- 术前单独骨内750 mg头孢呋辛可最小化全身暴露并维持有效浓度,提示其安全性和作为首选预防策略的潜力。
研究设计与样本
- 随机试验,纳入30例初次全膝关节置换患者,分为骨内头孢呋辛750 mg组(C750IO组)、骨内头孢呋辛1,500 mg组(C1500IO组)和静脉头孢呋辛1,500 mg组(C1500IV组)。
- 所有组术前均未接受其他静脉抗生素。
- 术中采集9份组织样本(股骨或胫骨骨样本、手术区域滑膜和脂肪样本)及2次全身血样检测头孢呋辛浓度。
- 记录术中生命体征、术后第1天和第3天炎症标志物及肝肾功能,以及术后3个月内并发症。
主要发现
- C750IO组和C1500IO组组织头孢呋辛浓度高于C1500IV组(P < 0.05)。
- 除近端胫骨骨样本外,C750IO组与C1500IO组组织头孢呋辛浓度无显著差异(P > 0.05)。
- IO组术中血药浓度低于C1500IV组(P < 0.05),但C1500IO组松止血带后水平超过其他组。
- 各组间发生的生命体征无差异(P > 0.05)。
- C1500IV组术后炎症标志物水平高于C750IO组和C1500IO组,C750IO组术后第3天红细胞沉降率水平显著低于C1500IV组(P = 0.017)。
关键数值与推荐
- 骨内头孢呋辛750 mg组和1,500 mg组组织浓度均高于静脉1,500 mg组(P < 0.05)。
- 除近端胫骨骨样本外,骨内750 mg组与1,500 mg组组织浓度无显著差异(P > 0.05)。
- 骨内组术中血药浓度低于静脉1,500 mg组(P < 0.05)。
- 骨内750 mg组术后第3天红细胞沉降率显著低于静脉1,500 mg组(P = 0.017)。
临床怎么用
- 作者认为术前单独骨内750 mg头孢呋辛可最小化全身暴露并维持有效组织浓度,提示其安全性和作为首选预防策略的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraosseous regional administration (IORA) of vancomycin for preventing infection in total knee arthroplasty (TKA) achieves high local tissue concentrations and enhances efficacy when combined with intravenous (IV) cephalosporins. This study evaluated the safety and efficacy of standalone intraosseous (IO) cefuroxime for TKA infection prophylaxis and determined its optimal dose. METHODS: There were 30 primary TKA patients divided into three groups: IO administration of 750 mg cefuroxime (C750IO group), IO administration of 1,500 mg cefuroxime (C1500IO group), and IV administration of 1,500 mg cefuroxime (C1500IV group). All groups received no other IV antibiotics preoperatively. During surgery, nine tissue samples were collected: bone samples were collected from the femur or tibia, synovial and fat samples were collected from the surgical area, and systemic blood samples were collected twice to detect cefuroxime levels. Intraoperative vital signs, inflammatory markers, and liver/kidney function on days one and three, and postoperative and complications within three months were recorded. RESULTS: The C750IO and C1500IO groups showed higher tissue cefuroxime concentrations than the C1500IV group (P < 0.05). Except for the proximal tibial bone sample, there were no significant differences in cefuroxime concentrations between the C750IO and C1500IO groups (P > 0.05). Intraoperative blood concentrations were lower in the IO groups compared to C1500IV (P < 0.05), but post-tourniquet-release levels in C1500IO exceeded other groups. There were no intergroup differences in vital signs that occurred (P > 0.05). Postoperative inflammatory marker levels were higher in the C1500IV group than in the C750IO and C1500IO groups, with significantly lower erythrocyte sedimentation rate levels in the C750IO group on postoperative day three compared to the C1500IV group (P = 0.017). No infections or adverse drug events occurred within three months postoperatively. CONCLUSIONS: Intraosseous cefuroxime (750 or 1500 mg) achieved higher local tissue concentrations than IV 1,500 mg in TKA. Preoperative IO 750 mg cefuroxime alone minimized systemic exposure while maintaining effective concentrations, suggesting its safety and potential as a preferred prophylactic strategy.
引用
- Liu T, Zhao R, Zhang H, et al. Preoperative Stand-Alone Intraosseous Cefuroxime in Total Knee Arthroplasty: A Randomized Trial Demonstrating Superior Tissue Concentrations and Improved Efficiency. J Arthroplasty. 2025. PMID: 40803562. doi:10.1016/j.arth.2025.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。